A trial looking at obinutuzumab with chemotherapy for follicular lymphoma (GALLIUM)

Coronavirus and cancer

We know it’s a worrying time for people with cancer, we have information to help. If you have symptoms of cancer contact your doctor.

Read our information about coronavirus and cancer

Coronavirus and cancer

We know it’s a worrying time for people with cancer, we have information to help. If you have symptoms of cancer contact your doctor.

Read our information about coronavirus and cancer

Cancer type:

Low grade lymphoma
Lymphoma
Non-Hodgkin lymphoma

Status:

Results

Phase:

Phase 3

This trial compared obinutuzumab with rituximab for a type of low grade non Hodgkin lymphoma (NHL) called follicular lymphoma.

More about this trial

Doctors often use chemotherapy and a type of targeted cancer drug called rituximab to treat low grade non Hodgkin lymphoma (NHL) such as follicular lymphoma. This treatment works well for many people, but the lymphoma can come back, and you need to have more treatment.

Obinutuzumab (Ga101) is another type of targeted cancer treatment. It works in a similar way to rituximab. People in this trial had chemotherapy and either obinutuzumab or rituximab.

The aims of the trial were to:

  • find out if obinutuzumab is better than rituximab for follicular lymphoma
  • compare the side effects of the 2 drugs

Summary of results

Results
This trial recruited 1,202 people with follicular lymphoma. They were put into 1 of 2 groups at random, and:

  • 601 people had chemotherapy and obinutuzumab
  • 601 people had chemotherapy and rituximab

The research team looked at how well the different treatments worked, and found that the lymphoma had gone away or got a bit better in:

  • 532 people (89%) who had chemotherapy and obinutuzumab
  • 522 people (87%) who had chemotherapy and rituximab

In 2017 they looked at the results to see how many people’s lymphoma had come back or got worse since treatment. They found it was higher for those who’d had rituximab:

  • 66 people (11%) who’d had chemotherapy and obinutuzumab
  • 98 people (16%) who’d had chemotherapy and rituximab

This means that people who had obinutuzumab are likely to have longer before their lymphoma starts to grow.

When they looked at how many people had died, they found it was similar in both groups:

  • 35 people (6%) who’d had chemotherapy and obinutuzumab
  • 46 people (8%) who’d had chemotherapy and rituximab

Side effects
The research team also looked at the side effects people had. More than 9 out of 10 people taking part had at least one side effect. But many were mild or short term.

A few more people who had obinutuzumab had side effects that were classed as serious. The most common side effects were a reaction to the injection, feeling sick and a drop in white blood cells.

Conclusion
The research team concluded that chemotherapy and obinutuzumab worked better than chemotherapy and rituximab for follicular lymphoma. But it caused more serious side effects.

We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Robert Marcus

Supported by

Experimental Cancer Medicine Centre (ECMC)
Genentech Ltd
NIHR Clinical Research Network: Cancer
Roche

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

8402

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think